Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2002

View Archived Issues

BM-17.0744 improves alterations in systemic and cardiac metabolism in diabetic db/db mice

Benefit:risk ratio of tamoxifen for breast cancer prophylaxis evaluated in large trial

Intravenous levetiracetam reported to be safe and effective as acute migraine Rx

Weight gain reported for olanzapine in patients with anorexia nervosa

Geron receives award for ongoing development of telomerase inhibitors for cancer

ICAAC news: Genelabs optimizes DNA-binding antifungal series

New metal complexes as prodrugs of antitumor compounds

U. of Toledo scientists prepare muscarinic receptor agonists

Integrin antagonists covered by 3-Dimensional patent

GSK presents novel beta3-adrenoceptor agonists with potential in obesity

Novel CCR2 modulators in early development at BMS

HIV RT inhibitors designed by team from Mayoly Spindler and U. of Geneva

Veronate evaluated in phase I trial for prevention of staphylococcal infections

CAT and Chugai sign licensing agreement to develop human monoclonal antibodies

Avant announces phase II Peru-15 results

Amarin and CellGate form research collaboration for targeted and controlled drug delivery

New oxazolidinone shows promise for staphylococcal infections

Preliminary results on use of argatroban for acute ischemic stroke

Development and preclinical testing of ChimeriVax West Nile virus vaccine

Development of water-soluble prodrugs of ravuconazole discussed at ICAAC

Overseas clinical study of Elaspol suspended

Medicis signs license and development agreement with Dow Pharmaceutical

FDA approves Augmentin XR for acute bacterial sinusitis and community-acquired pneumonia

Early phase III enrollment for extended-release Eligard

Hemopure BLA accepted for review

Optimer acquires license to Globo H vaccine

New trial of Genasense plus Gleevec in Gleevec-resistant CML patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...